{"id":"dabigatran-and-apixaban","safety":{"commonSideEffects":[{"rate":"2-5%","effect":"Bleeding (major and minor)"},{"rate":"5-11%","effect":"Dyspepsia"},{"rate":"1-2%","effect":"Gastrointestinal bleeding"},{"rate":"0.3-0.6%","effect":"Intracranial hemorrhage"}]},"_chembl":{"chemblId":"CHEMBL539697","moleculeType":"Small molecule","molecularWeight":"627.75"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dabigatran is a direct thrombin inhibitor that blocks Factor IIa, while apixaban is a Factor Xa inhibitor; both prevent the formation of blood clots by interrupting the coagulation cascade. This Phase 3 study likely compares the efficacy and safety of these two anticoagulants in a specific clinical population, such as patients with atrial fibrillation or venous thromboembolism.","oneSentence":"Dabigatran and apixaban are direct oral anticoagulants that inhibit blood clotting factors to prevent thromboembolism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:38.255Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention"}]},"trialDetails":[{"nctId":"NCT03568890","phase":"PHASE4","title":"Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2018-09-01","conditions":"Left Atrial Appendage Closure, Thrombosis, Stroke","enrollment":510},{"nctId":"NCT07497893","phase":"NA","title":"FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)","status":"NOT_YET_RECRUITING","sponsor":"Ewha Womans University Mokdong Hospital","startDate":"2026-12-01","conditions":"Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB), Gastrointestinal Hemorrhage (Clinically Important, Upper)","enrollment":1000},{"nctId":"NCT05387954","phase":"PHASE3","title":"PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-07","conditions":"Cryptogenic Ischemic Stroke, Patent Foramen Ovale","enrollment":792},{"nctId":"NCT06650501","phase":"PHASE4","title":"Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-01-15","conditions":"Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia","enrollment":300},{"nctId":"NCT04618913","phase":"","title":"Anticoagulation in Patients With Venous Thromboembolism and Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-14","conditions":"Neoplasms, Embolism","enrollment":1},{"nctId":"NCT05038228","phase":"","title":"High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-08-01","conditions":"Atrial Fibrillation","enrollment":1},{"nctId":"NCT04809818","phase":"PHASE1","title":"A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects","status":"COMPLETED","sponsor":"Lumosa Therapeutics Co., Ltd.","startDate":"2021-03-21","conditions":"Acute Ischemic Stroke","enrollment":65},{"nctId":"NCT07242326","phase":"","title":"SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)","status":"ENROLLING_BY_INVITATION","sponsor":"Kotyora Family Medicine Health Management and Education Association","startDate":"2025-12-15","conditions":"Medication Adherence, Atrial Fibrillation (AF), Direct Oral Anticoagulants (DOACs)","enrollment":1000},{"nctId":"NCT04611893","phase":"","title":"Monitoring of NOAC Therapy: Standardizing Reference Intervals","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2020-11-05","conditions":"Ischemic Stroke, Stroke, Acute, Stroke Syndrome","enrollment":308},{"nctId":"NCT05825573","phase":"PHASE3","title":"Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-05-15","conditions":"Intracardiac Thrombus, STEMI, Heart Failure","enrollment":340},{"nctId":"NCT07358416","phase":"","title":"Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2025-05-01","conditions":"Thrombosis, Bleeding, Cerebral Hypoxia During and/or Resulting From A Procedure","enrollment":500},{"nctId":"NCT04045665","phase":"PHASE3","title":"Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-12-13","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":3200},{"nctId":"NCT05838664","phase":"","title":"A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-07-07","conditions":"Atrial Fibrillation","enrollment":2140403},{"nctId":"NCT03463317","phase":"PHASE4","title":"Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-02-28","conditions":"Atrial Fibrillation","enrollment":912},{"nctId":"NCT04684212","phase":"NA","title":"Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF","status":"WITHDRAWN","sponsor":"Brian O'Neill MD","startDate":"2024-06-01","conditions":"Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA","enrollment":""},{"nctId":"NCT06581965","phase":"PHASE4","title":"inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2024-11-11","conditions":"Venous Thromboembolism, Venous Thromboses, Pulmonary Embolism","enrollment":10078},{"nctId":"NCT03778502","phase":"","title":"DOAC in Unusual Site Venous Thrombosis","status":"COMPLETED","sponsor":"University of Malta","startDate":"2019-10-01","conditions":"Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis","enrollment":358},{"nctId":"NCT03087487","phase":"","title":"Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-06-01","conditions":"Non-Valvular Atrial Fibrillation","enrollment":466991},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT07011095","phase":"EARLY_PHASE1","title":"DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial","status":"NOT_YET_RECRUITING","sponsor":"Population Health Research Institute","startDate":"2025-09-03","conditions":"Atrial Fibrillation (AF), Stroke (in Patients With Atrial Fibrillation)","enrollment":100},{"nctId":"NCT06983795","phase":"","title":"Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-07","conditions":"Ischemic Stroke, Patent Foramen Ovale","enrollment":1000},{"nctId":"NCT03129490","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":11000},{"nctId":"NCT04700826","phase":"PHASE4","title":"Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2021-06-01","conditions":"Atrial Fibrillation","enrollment":3000},{"nctId":"NCT03129555","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":5000},{"nctId":"NCT06957366","phase":"NA","title":"Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-04-01","conditions":"Atrial Fibrillation (AF), VTE","enrollment":920},{"nctId":"NCT05735639","phase":"PHASE4","title":"THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2024-01-22","conditions":"Venous Thromboembolism, Varicose Veins","enrollment":6660},{"nctId":"NCT04394234","phase":"","title":"A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-05-15","conditions":"Uterine Hemorrhage","enrollment":961985},{"nctId":"NCT06449469","phase":"NA","title":"The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-05-01","conditions":"Aortic Valve Stenosis, Cardiovascular Diseases, Heart Diseases","enrollment":352},{"nctId":"NCT06322953","phase":"PHASE3","title":"Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage","status":"RECRUITING","sponsor":"Walton Centre NHS Foundation Trust","startDate":"2025-03-10","conditions":"Traumatic Intracranial Haemorrhage","enrollment":1084},{"nctId":"NCT06571149","phase":"PHASE4","title":"Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-03-14","conditions":"Ischemic Stroke","enrollment":906},{"nctId":"NCT05750680","phase":"","title":"DOCE Study Interaction Between Direct Oral Anticoagulants and Drug-metabolizing Enzyme Inducers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-05-13","conditions":"Atrial Fibrillation, Thromboembolism, Venous","enrollment":23},{"nctId":"NCT05068414","phase":"","title":"Assessment of the Incidence of Hemorrhagic and Ischemic Events in Post-angioplasty in Anticoagulated Coronary Patients with Atrial Fibrillation","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2021-04-12","conditions":"Atrial Fibrillation, Acute Coronary Syndrome, Thrombosis","enrollment":122},{"nctId":"NCT04234698","phase":"","title":"Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In Colombia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-03-22","conditions":"Atrial Fibrillation","enrollment":2076},{"nctId":"NCT05378035","phase":"","title":"DOAC in Chinese Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-09-28","conditions":"Atrial Fibrillation, Stroke, Stroke, Acute","enrollment":427},{"nctId":"NCT03996772","phase":"PHASE3","title":"PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2019-06-03","conditions":"Atrial Fibrillation, Intracerebral Hemorrhage","enrollment":319},{"nctId":"NCT03062319","phase":"PHASE4","title":"Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis","status":"TERMINATED","sponsor":"National Hospital Organization Osaka National Hospital","startDate":"2017-04-06","conditions":"Ischemic Stroke, Atrial Fibrillation, Atherothrombosis","enrollment":321},{"nctId":"NCT01924065","phase":"PHASE3","title":"Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation","status":"COMPLETED","sponsor":"Suleyman Demirel University","startDate":"2013-08","conditions":"Atrial Fibrillation, Cardioversion, Cerebrovascular Stroke","enrollment":112},{"nctId":"NCT06615596","phase":"EARLY_PHASE1","title":"Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-01","conditions":"Atrial Fibrillation (AF)","enrollment":3160},{"nctId":"NCT03596502","phase":"","title":"Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin)","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-02-01","conditions":"Atrial Fibrillation, Ischemic Stroke, Systemic Embolization","enrollment":402764},{"nctId":"NCT06556446","phase":"","title":"Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2024-01-01","conditions":"Ischemic Stroke","enrollment":2800},{"nctId":"NCT06551415","phase":"PHASE3","title":"Dabigatran Versus Apixaban in Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2021-08-01","conditions":"Cerebral Venous Sinus Thrombosis","enrollment":200},{"nctId":"NCT04249401","phase":"","title":"Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-03-01","conditions":"Atrial Fibrillation","enrollment":134897},{"nctId":"NCT05472766","phase":"NA","title":"Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2022-11-24","conditions":"Subdural Hematoma, Atrial Fibrillation","enrollment":1},{"nctId":"NCT03759938","phase":"NA","title":"OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2019-06-18","conditions":"Stroke, Acute, Atrial Fibrillation","enrollment":3648},{"nctId":"NCT05006287","phase":"PHASE2","title":"The Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Paul's Hospital, Canada","startDate":"2022-10-12","conditions":"Atrial Fibrillation","enrollment":100},{"nctId":"NCT05802576","phase":"","title":"Study of Interference Between Oral Anticoagulants and Heparin During Ablation of Atrial Fibrillation (AF) or Left Atrial Tachycardia (GAD) by Catheter.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-07-08","conditions":"Atrial Fibrillation, Atrial Tachycardia","enrollment":100},{"nctId":"NCT06057467","phase":"NA","title":"Early Versus Late Initiation of Anticoagulation in Mild-to-moderate AIS Patients With NVAF","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-15","conditions":"Acute Ischemic Stroke, Atrial Fibrillation","enrollment":2351},{"nctId":"NCT04042155","phase":"","title":"Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)","status":"UNKNOWN","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2019-07-29","conditions":"Atrial Fibrillation, Recurrent Venous Thromboembolism","enrollment":1600},{"nctId":"NCT04662515","phase":"","title":"NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications","status":"COMPLETED","sponsor":"Malmö University","startDate":"2016-06-01","conditions":"Surgery, Oral, Hemorrhage, Postoperative Complications","enrollment":216},{"nctId":"NCT03642509","phase":"NA","title":"Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2019-01-01","conditions":"Atrial Fibrillation, Stroke","enrollment":750},{"nctId":"NCT02744092","phase":"NA","title":"Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2016-12-13","conditions":"Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT)","enrollment":811},{"nctId":"NCT05022563","phase":"","title":"Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-31","conditions":"Venous Thromboembolism","enrollment":55759},{"nctId":"NCT03148457","phase":"NA","title":"Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2017-11-06","conditions":"Ischaemic Stroke","enrollment":2013},{"nctId":"NCT04679298","phase":"","title":"Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants Extended","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2021-01-05","conditions":"Anticoagulation With Direct Oral Anticoagulants","enrollment":80},{"nctId":"NCT04297150","phase":"","title":"Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..","status":"UNKNOWN","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2020-06-18","conditions":"Atrial Fibrillation","enrollment":700},{"nctId":"NCT03977363","phase":"","title":"The Portuguese Survey on Anticoagulated Patients Register (START-Portugal-Register)","status":"TERMINATED","sponsor":"CHAD","startDate":"2020-01-27","conditions":"Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases or Prosthesis","enrollment":25},{"nctId":"NCT04195113","phase":"","title":"Perioperative Anticoagulant Use for Surgery Evaluation Emergency Registry","status":"COMPLETED","sponsor":"McMaster University","startDate":"2019-08-07","conditions":"Atrial Fibrillation, Venous Thromboembolism, Arterial Vascular Disease","enrollment":242},{"nctId":"NCT03572972","phase":"","title":"Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-01-31","conditions":"Atrial Fibrillation","enrollment":64684},{"nctId":"NCT04808934","phase":"","title":"NOAC Portuguese Real World Study","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2020-06-01","conditions":"Stroke, Systemic Embolism, Major Bleeding","enrollment":""},{"nctId":"NCT04002011","phase":"PHASE2","title":"DOAC Versus VKA After Cardiac Surgery","status":"WITHDRAWN","sponsor":"Laval University","startDate":"2022-03-09","conditions":"Anticoagulant-induced Bleeding","enrollment":""},{"nctId":"NCT02219984","phase":"","title":"START-Register: Survey on Anticoagulated Patients Register","status":"RECRUITING","sponsor":"GUALTIERO PALARETI","startDate":"2011-10","conditions":"Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases or Prosthesis","enrollment":15410},{"nctId":"NCT01588119","phase":"","title":"Register for New Oral Anticoagulants","status":"UNKNOWN","sponsor":"GWT-TUD GmbH","startDate":"2011-11","conditions":"Anticoagulation Treatment","enrollment":5000},{"nctId":"NCT02353585","phase":"","title":"Novel Oral Anticoagulants in Stroke Patients","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2014-12","conditions":"Ischemic Stroke, Intracranial Hemorrhages","enrollment":1050},{"nctId":"NCT03292666","phase":"","title":"Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-01-01","conditions":"Venous Thromboembolism, Anticoagulants and Bleeding Disorders","enrollment":39603},{"nctId":"NCT04151680","phase":"","title":"Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk Patients","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2019-12-01","conditions":"Ischemic Heart Disease, Atrial Fibrillation","enrollment":100},{"nctId":"NCT03942913","phase":"","title":"Prospective Real-world Registry Describing Treatment Regimens","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2019-10-10","conditions":"Subject Under Anticoagulant","enrollment":573},{"nctId":"NCT05491460","phase":"PHASE1","title":"Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects","status":"UNKNOWN","sponsor":"Doasense GmbH","startDate":"2022-07-01","conditions":"Anticoagulant Therapy","enrollment":24},{"nctId":"NCT03181386","phase":"PHASE3","title":"Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2017-05-03","conditions":"Atrial Fibrillation, Periodontal Disease, Hemorrhage","enrollment":60},{"nctId":"NCT02640222","phase":"","title":"APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-01-01","conditions":"Anticoagulation","enrollment":321501},{"nctId":"NCT02754154","phase":"","title":"Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-12-31","conditions":"Atrial Fibrillation","enrollment":321182},{"nctId":"NCT03182829","phase":"","title":"In Vitro Diagnostic Test for DOAC in Urine","status":"COMPLETED","sponsor":"Doasense GmbH","startDate":"2018-08-22","conditions":"Anticoagulant Therapy","enrollment":880},{"nctId":"NCT05319340","phase":"NA","title":"I.M. Sechenov First Moscow State Medical University (Sechenov University)","status":"COMPLETED","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2014-01-15","conditions":"Anticoagulants","enrollment":1000},{"nctId":"NCT02286414","phase":"","title":"Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02","conditions":"Atrial Fibrillation","enrollment":159},{"nctId":"NCT05027061","phase":"","title":"A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2021-04-02","conditions":"Non-Valvular Atrial Fibrillation (NVAF)","enrollment":11776},{"nctId":"NCT03965741","phase":"","title":"Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-05-30","conditions":"Venous Thromboembolism (VTE)","enrollment":97765},{"nctId":"NCT02701062","phase":"PHASE4","title":"AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)","status":"COMPLETED","sponsor":"AtriCure, Inc.","startDate":"2016-02","conditions":"Post-Operative Atrial Fibrillation","enrollment":562},{"nctId":"NCT04056143","phase":"","title":"Precision Medicine Platform for Novel Oral Anticoagulants","status":"UNKNOWN","sponsor":"Kaohsiung Medical University","startDate":"2019-01-02","conditions":"Anticoagulant Adverse Reaction","enrollment":500},{"nctId":"NCT02464488","phase":"","title":"New Oral Direct Anticoagulants in Patients 80 Years Old and Over : a Population Pharmacokinetics Study","status":"COMPLETED","sponsor":"Hôpital Charles Foix","startDate":"2015-01-01","conditions":"Atrial Fibrillation","enrollment":232},{"nctId":"NCT03520868","phase":"","title":"Heparin Requirements in Patients Undergoing Atrial Fibrillation Ablation on Coumadin vs NOACs","status":"COMPLETED","sponsor":"Steward St. Elizabeth's Medical Center of Boston, Inc.","startDate":"2017-05-05","conditions":"Atrial Fibrillation","enrollment":60},{"nctId":"NCT04891861","phase":"PHASE3","title":"Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial Hemorrhage","status":"UNKNOWN","sponsor":"University of Texas at Austin","startDate":"2021-07-01","conditions":"Anticoagulants; Increased","enrollment":100},{"nctId":"NCT04878497","phase":"","title":"Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-03-30","conditions":"Atrial Fibrillation, Frailty, Anticoagulant-induced Bleeding","enrollment":1000000},{"nctId":"NCT04099238","phase":"","title":"Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-10-01","conditions":"Atrial Fibrillation","enrollment":3739},{"nctId":"NCT04192916","phase":"","title":"Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms","status":"COMPLETED","sponsor":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","startDate":"2019-09-01","conditions":"Myeloproliferative Neoplasm","enrollment":442},{"nctId":"NCT04412291","phase":"PHASE2","title":"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2020-06-11","conditions":"Covid-19","enrollment":120},{"nctId":"NCT03568916","phase":"","title":"Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2016-11","conditions":"Atrial Fibrillation, Ischemic Stroke, Systemic Embolization","enrollment":227579},{"nctId":"NCT02825394","phase":"","title":"Specific PoC Testing of Coagulation in Patients Treated With DOAC 1","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2016-10-13","conditions":"Anticoagulation With NOAC","enrollment":160},{"nctId":"NCT03715725","phase":"","title":"A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.","status":"TERMINATED","sponsor":"Bayer","startDate":"2018-10-31","conditions":"Non-valvular Atrial Fibrillation","enrollment":70000},{"nctId":"NCT02935855","phase":"PHASE4","title":"ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)","status":"COMPLETED","sponsor":"University of Pavia","startDate":"2015-09","conditions":"Diabetes","enrollment":300},{"nctId":"NCT03474757","phase":"","title":"Treatment Pattern of NOACs (Non-vitamin K Oral Anticoagulants) in Outpatient Users in Colombian Databases","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-02-28","conditions":"Atrial Fibrillation","enrollment":10528},{"nctId":"NCT04518735","phase":"","title":"Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2020-04-01","conditions":"Covid19","enrollment":1707},{"nctId":"NCT04505475","phase":"","title":"Oral Surgery in Patients Taking Direct Oral Anticoagulants","status":"COMPLETED","sponsor":"University of Novi Sad","startDate":"2015-05-25","conditions":"Anticoagulants and Bleeding Disorders, Surgery, Postoperative Hemorrhage","enrollment":82},{"nctId":"NCT03465735","phase":"NA","title":"Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2017-01-13","conditions":"Acute DVT of Lower Extremity","enrollment":15},{"nctId":"NCT03537521","phase":"","title":"Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists (RADOA). Focus on New Antidots","status":"WITHDRAWN","sponsor":"Cardioangiologisches Centrum Bethanien","startDate":"2020-04","conditions":"Severe Bleeding, Urgent Surgery","enrollment":""},{"nctId":"NCT01722786","phase":"","title":"Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists","status":"COMPLETED","sponsor":"Cardioangiologisches Centrum Bethanien","startDate":"2014-04","conditions":"Severe Bleeding, Urgent Surgery","enrollment":272},{"nctId":"NCT03760874","phase":"","title":"Atrial Fibrillation Research Database","status":"UNKNOWN","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2013-06-13","conditions":"Anticoagulants and Bleeding Disorders, Atrial Fibrillation","enrollment":5000},{"nctId":"NCT03119116","phase":"","title":"Use of Direct Oral Anticoagulants in UK","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-05-15","conditions":"Stroke","enrollment":31336},{"nctId":"NCT04291287","phase":"","title":"Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)","status":"UNKNOWN","sponsor":"Scientific Institute San Raffaele","startDate":"2020-01-25","conditions":"Atrial Fibrillation, Myocardial Infarction, Anticoagulant-induced Bleeding","enrollment":1500},{"nctId":"NCT02998905","phase":"PHASE2","title":"NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2017-04-26","conditions":"Atrial Fibrillation, Intracerebral Hemorrhage","enrollment":30},{"nctId":"NCT02635230","phase":"","title":"What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.","status":"UNKNOWN","sponsor":"R&D Cardiologie","startDate":"2014-06","conditions":"Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes","enrollment":2200},{"nctId":"NCT04047654","phase":"","title":"Efficacy and Safety of Oral Anticoagulants Among Thai Octogenarians With Nonvalvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2019-04-22","conditions":"Stroke, Atrial Fibrillation","enrollment":327}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3105,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pradaxa and Eliquis"],"phase":"phase_3","status":"active","brandName":"Dabigatran and Apixaban","genericName":"Dabigatran and Apixaban","companyName":"University of Sao Paulo General Hospital","companyId":"university-of-sao-paulo-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dabigatran and Apixaban are small molecule direct oral anticoagulants used to treat conditions such as atrial fibrillation, thromboembolism, and venous conditions, as well as to prevent intracerebral hemorrhage. They work by inhibiting blood clotting and are available in oral tablet form, with an in vitro diagnostic test also available to detect their presence in urine.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}